Literature DB >> 17627247

Antithymocyte globulin impairs T-cell/antigen-presenting cell interaction: disruption of immunological synapse and conjugate formation.

Michael Haidinger1, René Geyeregger, Marko Poglitsch, Thomas Weichhart, Maximilian Zeyda, Barbara Vodenik, Thomas M Stulnig, Georg A Böhmig, Walter H Hörl, Marcus D Säemann.   

Abstract

Antithymocyte globulin (ATG) is employed for the treatment and prevention of acute organ rejection after transplantation. However, the mechanisms underlying its immunomodulatory capacities beyond cellular depletion remains ill defined. A stable interaction between T-cells and professional antigen-presenting cells (APC) and full T-cell stimulation requires a complex molecular rearrangement at the T-cell/APC interface, the so called immunological synapse. Here we investigated, whether ATG affects T-cell/APC interactions. ATG concentration and time-dependently inhibited relocalization of the T-cell receptor/CD3 complex as well as adhesion molecules and cytoskeletal proteins of human peripheral blood T-cells and a human T-cell line towards the APC contact site. Moreover, ATG-treated peripheral blood T-cells were incapable to form conjugates with APCs. In conclusion, ATG impairs T-cell/APC conjugate formation, a mechanism that may help to understand the functional inactivation of peripheral blood T-cells that have escaped cellular depletion after ATG treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627247     DOI: 10.1097/01.tp.0000266677.45428.80

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

Review 1.  Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly.

Authors:  Coco de Koning; Rick Admiraal; Stefan Nierkens; Jaap Jan Boelens
Journal:  Stem Cell Investig       Date:  2017-05-16

2.  Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.

Authors:  Dipenkumar Modi; Vijendra Singh; Seongho Kim; Lois Ayash; Abhinav Deol; Voravit Ratanatharathorn; Joseph P Uberti
Journal:  Ann Hematol       Date:  2021-02-16       Impact factor: 3.673

3.  Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity.

Authors:  Diana Stauch; Annelie Dernier; Elizabeth Sarmiento Marchese; Kristina Kunert; Hans-Dieter Volk; Johann Pratschke; Katja Kotsch
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

4.  In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children.

Authors:  Doris M Ponce; Mary Eapen; Rodney Sparapani; Tracey A O'Brien; Ka Wah Chan; Junfang Chen; John Craddock; Kirk R Schultz; John E Wagner; Miguel-Angel Perales; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-29       Impact factor: 5.742

5.  Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation.

Authors:  Mark Bosch; Manveer Dhadda; Mette Hoegh-Petersen; Yiping Liu; Laura M Hagel; Peter Podgorny; Alejandra Ugarte-Torres; Faisal M Khan; Joanne Luider; Iwona Auer-Grzesiak; Adnan Mansoor; James A Russell; Andrew Daly; Douglas A Stewart; David Maloney; Michael Boeckh; Jan Storek
Journal:  Cytotherapy       Date:  2012-09-18       Impact factor: 5.414

6.  Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.

Authors:  Mehdi Hamadani; William Blum; Gary Phillips; Patrick Elder; Leslie Andritsos; Craig Hofmeister; Lynn O'Donnell; Rebecca Klisovic; Sam Penza; Ramiro Garzon; David Krugh; Thomas Lin; Thomas Bechtel; Don M Benson; John C Byrd; Guido Marcucci; Steven M Devine
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-01       Impact factor: 5.742

Review 7.  Conditioning regimens for hematopoietic cell transplantation: one size does not fit all.

Authors:  Boglarka Gyurkocza; Brenda M Sandmaier
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

Review 8.  Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.

Authors:  Kathryn S Ivy; P Brent Ferrell
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

9.  Immune dysregulation in myelodysplastic syndrome.

Authors:  Chiharu Sugimori; Alan F List; Pearlie K Epling-Burnette
Journal:  Hematol Rep       Date:  2010-01-26

Review 10.  Immune Mechanisms in Myelodysplastic Syndrome.

Authors:  Andreas Glenthøj; Andreas Due Ørskov; Jakob Werner Hansen; Sine Reker Hadrup; Casey O'Connell; Kirsten Grønbæk
Journal:  Int J Mol Sci       Date:  2016-06-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.